Kestra Medical Technologies, Ltd. filed an 8-K on September 10, 2026, reporting the voting results from its 2026 annual general meeting of shareholders held on September 9, 2026.

Key Highlights

  • Shareholder turnout: 55,399,491 common shares were voted, representing approximately 94.53% of the 58,603,121 shares outstanding and entitled to vote as of the July 17, 2026 record date.
  • Directors elected: Raymond W. Cohen, Kevin Reilly, and Traci S. Umberger were each elected as Class II directors to serve until the 2029 annual meeting.
  • Auditor ratified: Shareholders ratified the appointment of PricewaterhouseCoopers as independent registered public accounting firm for the fiscal year ending April 30, 2027.
  • PwC ratification vote: 55,356,225 shares voted for, 8,469 against, and 34,797 abstained.
  • Emerging growth company: The registrant indicated it is an emerging growth company as defined under applicable securities regulations.

Director Elections and Auditor Ratification at Kestra Medical's 2026 Annual Meeting

According to the filing, Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) held its 2026 annual general meeting on September 9, 2026, with 55,399,491 shares voted in person or by proxy, representing approximately 94.53% of the shares outstanding as of the July 17, 2026 record date of 58,603,121 shares.

Under Proposal 1, the filing disclosed that three Class II director nominees were elected to serve until the 2029 annual meeting of shareholders. Raymond W. Cohen received 37,334,685 votes for and 10,779,640 against, with 34,843 abstentions and 7,259,323 broker non-votes. Kevin Reilly received 38,900,190 votes for and 9,204,737 against, with 35,241 abstentions and 7,259,323 broker non-votes. Traci S. Umberger received 38,866,030 votes for and 9,238,943 against, with 35,195 abstentions and 7,259,323 broker non-votes.

Under Proposal 2, the filing reported that shareholders ratified the appointment of PricewaterhouseCoopers as the company's independent registered public accounting firm for the fiscal year ending April 30, 2027. The vote was 55,356,225 for, 8,469 against, and 34,797 abstentions, according to the filing. The 8-K was signed by Brian Webster, President and Chief Executive Officer, on September 10, 2026.

What Was Disclosed

Kestra Medical Technologies disclosed the shareholder voting results from its September 9, 2026 annual general meeting, covering the election of three Class II directors and the ratification of PricewaterhouseCoopers as its independent auditor for the fiscal year ending April 30, 2027.